cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14233233.v1
title: The economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in Denmark

description: To evaluate the economic burden associated with therapeutic inertia in patients with type 2 diabetes mellitus (T2D) in Denmark. The economic burden for a newly diagnosed Danish T2D population was estimated using a validated diabetes model (The Swedish Institute for Health Economics (IHE) Cohort model), based on achieving varying levels of glycemic control. The analyses were based on clinical data from the Danish Centre for Strategic Research (DD2) and supplemented with relevant Swedish data where variables were missing. The analysis estimated the economic burden for populations achieving different guideline-recommended targets for glycated hemoglobin (HbA<sub>1c</sub>) and for a number of therapeutic inertia scenarios. To estimate the population-level burden Danish specific epidemiology data were incorporated. All costs are reported in 2020 Danish kroner (DKK) and 2020 Euros (€). The baseline HbA<sub>1c</sub> level used for this analysis was 7.9% (63 mmol/mol), which was observed in newly diagnosed Danish T2D patients prior to their first anti-diabetic treatment. Therapeutic inertia was associated with substantial economic burden compared to achieving immediate glycemic control (target &lt;6.5% (&lt; 48 mmol/mol)). Per patient burdens were between 3,562 DKK and 20,160 DKK (€477 to €2,701) dependent on the duration of therapeutic inertia (1 - 7 years), with this further increased when indirect costs were included (9,649 DKK to 51,585 DKK [€1,393 to €6,912]). The economic burden at a population level was between 27 million DKK to 150 million DKK (€3.6 million to €20 million), dependent on the duration of therapeutic inertia, rising to 72 million DKK to 384 million DKK (€9.6 million to €51.4 million) when indirect costs were included. Achieving early and intensive glycemic control, thereby minimizing therapeutic inertia can lead to substantial savings for the Danish society, ranging between 72 million DKK and 384 million DKK (€9.6 million to €51.4 million) (1 – 7 years of therapeutic inertia). This study highlights that efforts to minimize therapeutic inertia, by securing timely intensification before individual HbA<sub>1c</sub> targets are exceeded, results in significant long-term cost savings in Denmark.
DOI: 10.6084/m9.figshare.12899366.v1
title: Delphi, non-RAND modified Delphi, RAND/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review

description: Increasing demand for reliable evidence in patient care and its delivery has necessitated the development of several approaches for generating quality evidence. In particular, the solicitation of expert opinion has been recognised as a reliable data collection method. However, there are variations and limitations in study approaches using expert opinion as a method of data collection, thereby necessitating the development of a standardised, novel consensus method. A systematic literature review was conducted to assess the characteristics of all studies utilising a “Delphi” or “Modified Delphi” methods between January 2008 and December 2018. A search framework was developed, and the review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In total, 764 studies met the study inclusion and exclusion criteria and were included in the review. Heterogeneity on core defining characteristics of the constituent study types was observed in this control group. These 764 studies were compared against the four case studies using the Jandhyala method. Four key themes were identified and discussed: Assessment of Forced or Observed consensus, Assessment and reporting of item Awareness and advisor awareness, Minimum expert engagement profile, and Efficiency of Minimum Engagement Profile. Existing consensus methodologies have undergone significant modifications by successive authors over time, including ones contradicting core principles where an original method had been defined. The Jandhyala method for generating group consensus and awareness is unique in observing consensus and measuring awareness of subject matter across experts. The Jandhyala method also improves upon the traditional Delphi-style methodologies, through the introduction of new insights into awareness of subject matter in the expert group. A wider application of the Jandhyala method is required to corroborate findings from this research.
DOI: 10.6084/m9.figshare.12899366
title: Delphi, non-RAND modified Delphi, RAND/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review

description: Increasing demand for reliable evidence in patient care and its delivery has necessitated the development of several approaches for generating quality evidence. In particular, the solicitation of expert opinion has been recognised as a reliable data collection method. However, there are variations and limitations in study approaches using expert opinion as a method of data collection, thereby necessitating the development of a standardised, novel consensus method. A systematic literature review was conducted to assess the characteristics of all studies utilising a “Delphi” or “Modified Delphi” methods between January 2008 and December 2018. A search framework was developed, and the review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In total, 764 studies met the study inclusion and exclusion criteria and were included in the review. Heterogeneity on core defining characteristics of the constituent study types was observed in this control group. These 764 studies were compared against the four case studies using the Jandhyala method. Four key themes were identified and discussed: Assessment of Forced or Observed consensus, Assessment and reporting of item Awareness and advisor awareness, Minimum expert engagement profile, and Efficiency of Minimum Engagement Profile. Existing consensus methodologies have undergone significant modifications by successive authors over time, including ones contradicting core principles where an original method had been defined. The Jandhyala method for generating group consensus and awareness is unique in observing consensus and measuring awareness of subject matter across experts. The Jandhyala method also improves upon the traditional Delphi-style methodologies, through the introduction of new insights into awareness of subject matter in the expert group. A wider application of the Jandhyala method is required to corroborate findings from this research.
DOI: 10.6084/m9.figshare.12994278.v1
title: The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data

description: Recognizing the value of anticancer treatments based on progression-free survival and overall survival may help decision making in healthcare policy. We aimed to measure and compare the impact of disease progression and terminal state prior to death on healthcare costs in HR+, HER2- ABC patients. We conducted a retrospective study using Korean nationwide health insurance claims database between 1 September 2012 and 31 August 2017. The impact of disease progression was estimated by measuring the average incremental monthly cost per patient during 1 year after progression compared to 1 year before progression. Death-related costs per patient per month (PPPM) were measured for those who died within 1 year after progression. Generalized estimating equation (GEE) was used to estimate the variations in PPPM costs by progression and death with adjustment for clinical factors. After progression, 1,636 patients expensed $2,892 per month more on average than before progression ($3762 vs. $870). The GEE analysis with adjustment for baseline characteristics showed that PPPM costs increased by 3.46 folds (95% CI = 3.06–3.93) after progression. Also, PPPM costs were 1.74 (95%CI = 1.43–2.12) times higher in patients who died within 1 year after progression relative to survived patients. When considering the interaction between progression and death, deceased patients showed higher increased ratio of PPPM costs after progression (4.91; <i>p</i>=value From the payer’s perspective, more healthcare costs incurred during the progression state than terminal state in HR+, HER2- ABC patients. The impact of disease progression emphasizes the importance of effectively treating HR+, HER2- ABC patients.
DOI: 10.6084/m9.figshare.12994278
title: The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data

description: Recognizing the value of anticancer treatments based on progression-free survival and overall survival may help decision making in healthcare policy. We aimed to measure and compare the impact of disease progression and terminal state prior to death on healthcare costs in HR+, HER2- ABC patients. We conducted a retrospective study using Korean nationwide health insurance claims database between 1 September 2012 and 31 August 2017. The impact of disease progression was estimated by measuring the average incremental monthly cost per patient during 1 year after progression compared to 1 year before progression. Death-related costs per patient per month (PPPM) were measured for those who died within 1 year after progression. Generalized estimating equation (GEE) was used to estimate the variations in PPPM costs by progression and death with adjustment for clinical factors. After progression, 1,636 patients expensed $2,892 per month more on average than before progression ($3762 vs. $870). The GEE analysis with adjustment for baseline characteristics showed that PPPM costs increased by 3.46 folds (95% CI = 3.06–3.93) after progression. Also, PPPM costs were 1.74 (95%CI = 1.43–2.12) times higher in patients who died within 1 year after progression relative to survived patients. When considering the interaction between progression and death, deceased patients showed higher increased ratio of PPPM costs after progression (4.91; <i>p</i>=value From the payer’s perspective, more healthcare costs incurred during the progression state than terminal state in HR+, HER2- ABC patients. The impact of disease progression emphasizes the importance of effectively treating HR+, HER2- ABC patients.
DOI: 10.5281/zenodo.4620934
title: "samplecrops" input archive for {sen2rts}

description: Input dataset containing an archive of Sentinel-2 derived products (NDVI, SCL, CLD) created with R package {sen2r} (Ranghetti et al., 2020) over some sample crops in the estate of Jolanda di Savoia (FE) of the farm Bonifiche Ferraresi. It is used as sample input archive in the documentation of the R package {sen2rts}.
DOI: 10.5281/zenodo.4620933
title: "samplecrops" input archive for {sen2rts}

description: Input dataset containing an archive of Sentinel-2 derived products (NDVI, SCL, CLD) created with R package {sen2r} (Ranghetti et al., 2020) over some sample crops in the estate of Jolanda di Savoia (FE) of the farm Bonifiche Ferraresi. It is used as sample input archive in the documentation of the R package {sen2rts}.
DOI: 10.5281/zenodo.4626689
title: SV training benchmark datasets

description: Read sets for each type of SV sniffles can identify - insertions, deletions, inversions, chromosomal translocations, tandem duplications.<br> SVs were added to an assembly of <em>E. coli sakai </em>(GenBank accession GCF_000008865.2), then 10x coverage worth of reads for the mutated genome were simulated using Badread (https://github.com/rrwick/Badread). The intention is for these reads to be aligned to GCF_000008865.2 (unmutated), then SV calling using sniffles to be performed. Sniffles performance at detecting the added SVs will be assessed. Detailed records of the SVs added per read set are also available on zenodo.
DOI: 10.5281/zenodo.4603454
title: SV training benchmark datasets

description: Read sets for each type of SV sniffles can identify - insertions, deletions, inversions, chromosomal translocations, tandem duplications.<br> SVs were added to an assembly of <em>E. coli sakai </em>(GenBank accession GCF_000008865.2), then 10x coverage worth of reads for the mutated genome were simulated using Badread (https://github.com/rrwick/Badread). The intention is for these reads to be aligned to GCF_000008865.2 (unmutated), then SV calling using sniffles to be performed. Sniffles performance at detecting the added SVs will be assessed. Detailed records of the SVs added per read set are also available on zenodo.
DOI: 10.5281/zenodo.4627048
title: The impact of human mobility data scales and processing on movement predictability

description: This file contains statistical measures of human individual movement trajectories calculated and analysed during the "The impact of human mobility data scales and processing on movement predictability" study submitted to Scientific Reports.
DOI: 10.6084/m9.figshare.14258459
title: Source_data_Fig6

description: <b>Typical <i>m/z</i> profiles as obtained by LA-REIMS analysis of human biofluids.</b> Number of features that were measured per <i>m/z</i>-class upon LA-REIMS analysis of saliva, plasma, urine, feces, milk, and sputum, in positive (a) and negative (b) ionization mode. For each matrix type, a single list of <i>m/z</i>-features was acquired, based on the processing of ten rawfiles (single burns), as obtained from ten different samples (i.e. individuals).
DOI: 10.6084/m9.figshare.14258459.v2
title: Source_data_Fig6

description: <b>Typical <i>m/z</i> profiles as obtained by LA-REIMS analysis of human biofluids.</b> Number of features that were measured per <i>m/z</i>-class upon LA-REIMS analysis of saliva, plasma, urine, feces, milk, and sputum, in positive (a) and negative (b) ionization mode. For each matrix type, a single list of <i>m/z</i>-features was acquired, based on the processing of ten rawfiles (single burns), as obtained from ten different samples (i.e. individuals).
DOI: 10.6084/m9.figshare.14258459.v1
title: Source_data_Fig6

description: <b>Typical <i>m/z</i> profiles as obtained by LA-REIMS analysis of human biofluids.</b> Number of features that were measured per <i>m/z</i>-class upon LA-REIMS analysis of saliva, plasma, urine, feces, milk, and sputum, in positive (a) and negative (b) ionization mode. For each matrix type, a single list of <i>m/z</i>-features was acquired, based on the processing of ten rawfiles (single burns), as obtained from ten different samples (i.e. individuals).
DOI: 10.6084/m9.figshare.14259880.v1
title: Platelet autophagic machinery involved in thrombosis through a novel linkage of AMPK-MTOR to sphingolipid metabolism

description: Basal macroautophagy/autophagy has recently been found in anucleate platelets. Platelet autophagy is involved in platelet activation and thrombus formation. However, the mechanism underlying autophagy in anucleate platelets require further clarification. Our data revealed that LC3-II formation and SQSTM1/p62 degradation were noted in H<sub>2</sub>O<sub>2</sub>-activated human platelets, which could be blocked by 3-methyladenine and bafilomycin A<sub>1</sub>, indicating that platelet activation may cause platelet autophagy. AMPK phosphorylation and MTOR dephosphorylation were also detected, and block of AMPK activity by the AMPK inhibitor dorsomorphin could reverse SQSTM1 degradation and LC3-II formation. Moreover, autophagosome formation was observed through transmission electron microscopy and deconvolution microscopy. These findings suggest that platelet autophagy was induced partly through the AMPK-MTOR pathway. In addition, increased LC3-II expression occurred only in H<sub>2</sub>O<sub>2</sub>-treated <i>Atg5</i><sup>f/f</sup> platelets, but not in H<sub>2</sub>O<sub>2</sub>-treated <i>atg5</i><sup>−/−</sup> platelets, providing further evidence that platelet autophagy occurs during platelet activation. <i>atg5</i><sup>−/−</sup> platelets also exhibited a lower aggregation in response to agonists, and platelet-specific <i>atg5</i><sup>−/−</sup> mice exhibited delayed thrombus formation in mesenteric microvessles and decreased mortality rate due to pulmonary thrombosis. Notably, metabolic analysis revealed that sphingolipid metabolism is involved in platelet activation, as evidenced by observed several altered metabolites, which could be reversed by dorsomorphin. Therefore, platelet autophagy and platelet activation are positively correlated, partly through the interconnected network of sphingolipid metabolism. In conclusion, this study for the first time demonstrated that AMPK-MTOR signaling could regulate platelet autophagy. A novel linkage between AMPK-MTOR and sphingolipid metabolism in anucleate platelet autophagy was also identified: platelet autophagy and platelet activation are positively correlated.
DOI: 10.5281/zenodo.4627066
title: Dataset for the paper: "An Exploratory Study on Automatic Identification of Assumptions in Software Development"

description: This is the dataset package for the paper: "An Exploratory Study on Automatic Identification of Assumptions in Software Development". It contains all the subdatasets in our experiment. Each file contains a subdataset, and the number of "Assumption" sentences are equal to the number of "Non-Assumption" sentences. For example, "D1000" denotes a subdatatset that contains 500 "Assumption" sentences and 500 "Non-Assumption" sentecnes.
DOI: 10.5281/zenodo.3969657
title: Dataset for the paper: "An Exploratory Study on Automatic Identification of Assumptions in Software Development"

description: This is the dataset package for the paper: "An Exploratory Study on Automatic Identification of Assumptions in Software Development". It contains all the subdatasets in our experiment. Each file contains a subdataset, and the number of "Assumption" sentences are equal to the number of "Non-Assumption" sentences. For example, "D1000" denotes a subdatatset that contains 500 "Assumption" sentences and 500 "Non-Assumption" sentecnes.
DOI: 10.5281/zenodo.4578940
title: Neologism dataset for "From plenipotentiary to puddingless: Users and uses of new words in early English letters"

description: These data files are related to the following paper: Säily, Tanja, Eetu Mäkelä and Mika Hämäläinen. 2021. From <em>plenipotentiary</em> to <em>puddingless</em>: Users and uses of new words in early English letters. Mika Hämäläinen, Niko Partanen & Khalid Alnajjar (eds.), <em>Multilingual Facilitation</em>, 153–169. Helsinki: University of Helsinki. doi:10.31885/9789515150257.15 Excel files: c17-data.xlsx = data from the 17th-century sample, 1640–1660 c18-data.xlsx = data from the 18th-century sample, 1760–1780 Sheets within the files: data = all neologism tokens found and their metadata from the OED and the CEEC sample = list of all letters in the sample and their metadata from the CEEC See readme.txt for more information.
DOI: 10.5281/zenodo.4578939
title: Neologism dataset for "From plenipotentiary to puddingless: Users and uses of new words in early English letters"

description: These data files are related to the following paper: Säily, Tanja, Eetu Mäkelä and Mika Hämäläinen. 2021. From <em>plenipotentiary</em> to <em>puddingless</em>: Users and uses of new words in early English letters. Mika Hämäläinen, Niko Partanen & Khalid Alnajjar (eds.), <em>Multilingual Facilitation</em>, 153–169. Helsinki: University of Helsinki. doi:10.31885/9789515150257.15 Excel files: c17-data.xlsx = data from the 17th-century sample, 1640–1660 c18-data.xlsx = data from the 18th-century sample, 1760–1780 Sheets within the files: data = all neologism tokens found and their metadata from the OED and the CEEC sample = list of all letters in the sample and their metadata from the CEEC See readme.txt for more information.
DOI: 10.6084/m9.figshare.12845469
title: Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis

description: Timely assessment of patient-specific prognosis is critical to oncology care involving a shared decision-making approach, but clinical prognostic factors traditionally used in NSCLC have limitations. We examine a proteomic test to address these limitations. This study examines the prognostic performance of the VeriStrat blood-based proteomic test that measures the inflammatory disease state of patients with advanced NSCLC. A systematic literature review (SLR) was performed, yielding cohorts in which the hazard ratio (HR) was reported for overall survival (OS) of patients with VeriStrat Poor (VSPoor) test results versus VeriStrat Good (VSGood). A study-level meta-analysis of OS HRs was performed in subgroups defined by lines of therapy and treatment regimens. Twenty-four cohorts met SLR criteria. Meta-analyses in five subgroups (first-line platinum-based chemotherapy, second-line single-agent chemotherapy, first-line EGFR-tyrosine kinase inhibitor (TKI) therapy, and second- and higher-line TKI therapy, and best supportive care) resulted in statistically significant (<i>p</i> ≤ .001) summary effect sizes for OS HRs of 0.42, 0.54, 0.41, 0.52, and 0.50, respectively, indicating increased OS by about two-fold for patients who test VSGood. No significant heterogeneity was seen in any subgroup (<i>p</i> &gt; .05). Advanced NSCLC patients classified VSGood have significantly longer OS than those classified VSPoor. The summary effect size for OS HRs around 0.4–0.5 indicates that the expected median survival of those with a VSGood classification is approximately 2–2.5 times as long as those with VSPoor. The robust prognostic performance of the VeriStrat test across various lines of therapy and treatment regimens has clinical implications for treatment shared decision-making and potential for novel treatment strategies.